Navigation Links
Febrile in Medical Technology

Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium

... early due to a higher-than-expected rate of febrile neutropaenia, a side effect involving a decrease ... is a clear demand for new therapies here. The febrile neutropaenia rates seen in this study ... control group. We have not seen evidence of febrile neutropaenia in our previous clinical experience ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... thrombocytopenia, neutropenia. Common: febrile neutropenia and infection without ... neutropenia, and thrombocytopenia. Common: febrile neutropenia. Very rare: Thrombocythaemia. ... an increased incidence of infections. Fatigue and febrile neutropenia also occur more frequently with this ...

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

... events occurring in more than 15 percent of patients included nausea, febrile neutropenia, vomiting, diarrhea and rash; most were grade 1 or 2. As ... effects including anemia, leukopenia, thrombocytopenia, neutropenia, and febrile neutropenia; and infection. Liver and kidney function should be assessed ...

Node-Negative Early Stage Breast Cancer Patients Benefit from Taxotere(R)-Based Chemotherapy

... severe event (24.6%) reported with the TAC regimen. The incidence of febrile neutropenia decreased to 6.5% with the use of G-CSF from the first cycle of TAC. The incidence of febrile neutropenia among patients treated with FAC was 2.3%. Grade 2-4 anemia was ...

Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent

... grade 4 in 5 patients and grade 3 in 13 patients. Only 1 patient developed febrile neutropenia. Following Zevalin administration grade 3-4 thrombocytopenia ... and 3 patients received platelet transfusions. Only 1 patient experience febrile neutropenia. The authors concluded "In this study we established the ...

Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine

... 4.6%). Commonly seen adverse events in the Taxotere-based regimen included febrile neutropenia (5.2%) and neutropenic infection (13.9%). The Tax 324 study ... cisplatin and fluorouracil (PF). Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 ...

Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th

... event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). ...

Investigational Cancer Drug BSI-201 Showed Clinical Benefit in 62% of Patients with Triple-Negative Metastatic Breast Cancer and Significantly Prolonged Survival

... effects included neutropenia [25/57 in patients treated with GC and BSI-201; 31/59 patients treated with GC alone], thrombocytopenia and anemia. No febrile neutropenia was observed in patients receiving BSI-201 combined with chemotherapy. BSI-201 did not add to the frequency or severity of adverse events ...

Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment

... event observed on the pixantrone arm was neutropenia in 41.2% of patients versus 19.4% on the comparator arm. However, the incidence of grade 3, 4 febrile neutropenia was only 7.4% versus 3.0% in the comparator arm. Grade 3, 4 infections had a similar incidence in both study arms (18% vs. 13%). ...

Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer

... treated with CRT alone (p=0.002). The most frequent severe (grade 3-4) adverse reactions were stomatitis (44% for IC+CRT vs. 31% for CRT) and febrile neutropenia (10% for IC+CRT vs. 1% for CRT). Other adverse events included neutropenia and asthenia. "These study results illustrate that this ...

Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer

... toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 percent of the planned picoplatin dose of 150 mg/meter squared ...

Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone

... treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent ...

Pixantrone Increases Progression-Free Survival by 81% Compared to Standard Chemotherapeutic Agents in Phase III Relapsed Aggressive non-Hodgkin's Lymphoma Trial

... treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent ...

Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer

... * Hematological toxicities and infections, including: - Neutropenia - 66% (Grade 3/4 57%) versus 65% (Grade 3/4 59%), with febrile neutropenia reported in 7% versus 6% of patients - Anemia - 20% (Grade 3/4 2%) versus 17% (Grade 3/4 1%) - Infection - 30% (Grade ...

Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia

... were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). Other serious adverse reactions included pneumonia, febrile neutropenia, leukopenia, intracranial hemorrhage, and pyrexia (Grade 3/4: 2%). Dose adjustments or modifications Tasigna may need ...

Dacogen(R) (decitabine for injection) Data Presented on a Phase II Clinical Trial in Elderly Patients with Acute Myeloid Leukemia (AML)

... reported." Besides myelosuppression, the most commonly reported adverse events considered possibly related to decitabine treatment were febrile neutropenia, fatigue, pneumonia, sepsis, dyspnea and bacteraemia. The five-day dosing regimen of Dacogen(R) is currently being further ...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

... dose, 1.3 mg/m(2) of VELCADE, 40 mg of dexamethasone and 15 mg of lenalidomide. -- The only two dose-limiting toxicities reported were febrile neutropenia and reactivation of the Herpes Zoster virus infection. -- The overall rate of serious adverse events (AEs) was 40 percent. ...

Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology

... a CR or CRp has not been reached. Grade 3 or higher non-hematologic adverse events occurring in more than 10 percent of patients include febrile neutropenia, mucosal inflammation and infections. The 30-day all-cause mortality rate was 17 percent, which compares favorably to standard induction ...

Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome

... regardless of the relationship to the study drug were neutropenic sepsis (5.4% / 1.1% / 3.3%), neutropenic infection (5.4% / 4.3% / 8.8%), and febrile neutropenia (4.3% / 3.3% / 5.5%), pulmonary hemorrhage (1.1% / 3.3% / 0%), and respiratory failure (2.2% / 3.3% / 1.1%) in the Elitek, ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... reactions were thrombocytopenia (37%), neutropenia (37%), anemia (23%) and elevated lipase (17%). Other serious adverse reactions included pneumonia, febrile neutropenia, leukopenia, intracranial hemorrhage and pyrexia (Grade 3/4: 2%). Dose adjustments or modifications Tasigna may need to be ...

Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint

... to the treatment assignments. The most common serious toxicities (>5%) seen in previous trials of pixantrone include grade 3 and 4 neutropenia and febrile neutropenia. Complete safety information is not yet available for the study, however, the study was monitored on an ongoing basis by an independent ...

Zevalin(R) Following Short-Course Chemotherapy with CHOP + Rituximab (CHOP-R) Doubles Complete Remission Rate in First-Line Treatment of Follicular Non- Hodgkin's Lymphoma

... most frequent toxicity associated with Zevalin was myelosuppression. Grade 3 to 4 neutropenia occurred in 28 (51%) of patients with one incidence of febrile neutropenia requiring hospitalization. Grade 3 to 4 thrombocytopenia occurred in 44% of patients. However, all 55 patients who received Zevalin had ...

Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium

... adverse events (greater than or equal to 5%) at the 48 mg/m2 dose were low: fatigue (14%), vomiting (6%) and infections (8%). Low rates of febrile neutropenia occurred in 8% of the 65 patients evaluable for safety at 48 mg/m2 dosed every three weeks and 6% of the 35 patients evaluable for safety ...

Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting

... of overall survival for responders was 3.9 months (2.5-28.6). The most common grade 3-5 adverse events, regardless of relation to treatment, were febrile neutropenia in 8 patients, and neutropenia and thrombocytopenia in 7 patients respectively. One patient died within 30 days of first induction ...

Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting

... population. With 65 patients evaluable for safety at the 48 mg/m(2) dose and 20 patients evaluable for safety at the 60 mg/m(2) dose, low rates of febrile neutropenia (<10%) or other Grade 3-4 adverse events (fatigue (12%), vomiting (5%) and infections (5% )) have been observed. Based on voreloxin's ...

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting

... were thrombocytopenia (37%), neutropenia (37%), anemia (23%), and elevated lipase (17%). Other serious adverse reactions included pneumonia, febrile neutropenia, leukopenia, intracranial hemorrhage, and pyrexia (Grade 3/4: 2%). Dose adjustments or modifications: Tasigna may need to be ...

Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases

... 3: 6.0%), hepatic (Grade 3: 5.2%), diarrhea (Grade 3: 5.2%), allergy (Grade 3/4: 4.4%), nausea (Grade 3: 4.3%), dysesthesia (Grade 3: 4.3%), and febrile neutropenia (Grade 3: 3.5%). In both patient groups, operative mortality remained very low (<1%): two deaths occurred after surgery in the standard ...

Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma

... 3/4 thrombocytopenia, neutropenia, and anemia occurred in 63 percent (36 of 57), 53 percent (30 of 57), and 23 percent (13 of 57), respectively. febrile neutropenia occurred in 9 percent (5 of 57) of patients. Patients who relapsed were treated with CHOP + rituximab as salvage therapy and all ...

Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer

... once every three weeks. The most common adverse events reported thus far include nausea, fatigue, vomiting and alopecia. There was a low rate of febrile neutropenia or other Grade 3/4 adverse events, and manageable Grade 1/2 nausea or vomiting. Based on the indications of clinical activity and the ...

Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)

... (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse ...

Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

... (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse ...

MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule

... (35.0%), constipation (33.6%), neutropenia (32.3%) and ecchymosis (30.5%). Other adverse reactions included dizziness (18.6%), chest pain (16.4%), febrile neutropenia (16.4%), myalgia (15.9%), injection site reaction (13.6%), aggravated fatigue (12.7%) and malaise (10.9%). The most common adverse ...

Pixantrone Versus Doxorubicin in CHOP-R Therapy for First-line Treatment of Aggressive Non-Hodgkin's Lymphoma Preliminary Results Presented at American Society of Hematology (ASH) Annual Meeting

... non-Hodgkin's lymphoma (NHL) showed patients who received pixantrone experienced less severe (grade 3/4) toxicities including severe infection and febrile neutropenia when compared to patients treated with standard doxorubicin-based therapy. A preliminary analysis of the study, known as PIX203, which is ...

TREANDA Demonstrates Substantial Efficacy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma

... the most common adverse events included myelosuppression, nausea, fatigue, diarrhea, vomiting and fever; the most common serious adverse events were febrile neutropenia and pneumonia. "The data presented at ASH, as well as from other studies using bendamustine, gives us great optimism that TREANDA may ...

TREANDA Significantly Improves Clinical Outcomes in Patients with Chronic Lymphocytic Leukemia Compared to Chlorambucil

... the most common adverse events included myelosuppression, nausea, fatigue, diarrhea, vomiting and fever; the most common serious adverse events were febrile neutropenia and pneumonia. "If approved, we believe TREANDA will be an important new treatment option for patients with CLL," said Dr. Lesley ...

Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML

... tract symptoms, including vomiting, nausea, and diarrhea; hematologic effects including anemia, leukopenia, thrombocytopenia, neutropenia, and febrile neutropenia; and infection. Liver and kidney function should be assessed prior to and during treatment with Clolar, as the liver is a target organ ...

Study Finds Fever may Lead to Improved Behavior in Children with Autism Spectrum Disorders

... up the signaling between brain regions. Understanding this "fever effect," including why and how connections are made between brain regions during a febrile (fever) state and not in an afebrile (without fever) state in children with ASD may provide valuable insight into the neurological basis of the ...

Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference

... SNS-595 was generally well tolerated at the current dosing level among nineteen patients with sufficient follow-up to yield safety data. Incidence of febrile neutropenia was 11 percent (2 of 19) among these patients. In addition, five percent (1 of 19) of these patients experienced grade 3/4 nausea and 11 ...

CuraGen Announces Top-Line Phase II Results on Velafermin

... endpoints evaluated included duration of oral mucositis, patient self-reported pain score, use of pain medications, the incidence and duration of febrile neutropenia, and use of enteral or parenteral nutrition. The complete results from CLN-12 will be presented in December at the American Society of ...

Taxotere(R) (docetaxel) Granted FDA Approval to Treat Locally Advanced Head and Neck Cancer Prior to Chemoradiotherapy and Surgery

... toxicity was 65% in the Taxotere arm (TPF) compared to 62% in the group receiving cisplatin and fluorouracil (PF). Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (84% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and ...
Other Contents
(Date:4/17/2015)... , April 17, 2015 ... concerns, and technological advancement to drive biometric systems ... until 2020   According to a ... Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems market in ... to register growth at CAGR of over 22% ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/13/2015)... CHICAGO , April 13, 2015  higi, a ... with ways to more fully engage with their communities ... its industry-leading, privacy protected and secure API.  ... API enables the most accessible, affordable, and convenient vehicle ... The API will ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
(Date:5/29/2015)... 2015 “In the current environment ... federal regulations, we provide education that will help ... are suffering from pain, within the boundaries of ... professor of rehabilitation medicine and President/Medical Director of ... Kansas. , A new flight of PAINWeekEnd Regional ...
(Date:5/29/2015)... Denver, CO (PRWEB) May 29, 2015 ... video from The Denver Foundation, community comes together to ... lead, to build neighborhoods and awareness of critical issues. ... in Metro Denver and beyond. , "What Community Does" ... oldest community foundation in Colorado, and released during the ...
(Date:5/29/2015)... Island (PRWEB) May 29, 2015 The ... 2015. The event, now closed to new registration, starts ... Adams. This exciting competitive running event demonstrates the ... to create a public benefit – in this case, ... coastal views around the famed Ocean Drive and passes ...
(Date:5/29/2015)... May 29, 2015 The Recovery ... substance abuse, and co-occurring mental health treatment facility, ... cutting for the general public on June 1st, ... The Recovery Village at Palmer Lake will offer ... programming, utilizing traditional and evidence-based therapies, in a ...
(Date:5/29/2015)... 2015 According to a recent HealthDay article, ... workers has a substance abuse problem - the data, which ... adults with full-time jobs, revealed that 9.5% of those workers ... (1) The National Council on Alcoholism and Drug Dependence (NCAAD) ... an estimated 70% of the 14.8 million illicit drug users ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:What Community Does: A New Video from The Denver Foundation 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 2Health News:The Newport 10 Miler at Fort Adams, an Outstanding Example of Event Marketing Helping in Preservation, is Now Completely Booked for 2015 3Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 2Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 3Health News:Novus Medical Detox Comments on Government Study Findings: One in 10 American Workers Struggling with Substance Abuse 4
Other TagsOther Tags